Search

Savara Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

5.27 -7.54

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.25

Max

5.72

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-5M

-37M

Darbuotojai

70

EBITDA

-3.8M

-37M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+95.96% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-10

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

125M

1.2B

Ankstesnė atidarymo kaina

12.81

Ankstesnė uždarymo kaina

5.27

Naujienos nuotaikos

By Acuity

60%

40%

292 / 340 reitingas Healthcare

Savara Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-13 20:02; UTC

Savara Inc shares are lower today, continuing a decline since Wednesday. The stock saw high trading volume amid no specific news.

2026-08-12 19:56; UTC

News

Savara Inc. shares are higher following Citizens' reaffirmation of its Outperform rating and $10 price target ahead of the MOLBREEVI PDUFA date.

2026-08-11 19:11; UTC

Savara Inc shares are lower today amid unusually high market volume. No specific news was identified to explain the decline.

2026-08-10 23:01; UTC

Savara Inc shares are lower in after-market trading, showing notable volatility without any specific news to explain the decline.

2026-08-07 19:36; UTC

Savara Inc is trading higher, benefiting from broader market gains following a weaker-than-expected jobs report that may delay Federal Reserve interest rate hikes.

2026-08-06 20:06; UTC

Savara Inc shares are higher today, recovering from earlier declines and trading above their 20-day moving average. No specific news was identified for the move.

2026-08-05 19:36; UTC

News

Savara Inc. shares are higher as the company advances its Biologics License Application for molgramostim, with a key PDUFA date approaching.

2026-08-04 23:01; UTC

Savara Inc shares are trading higher in after-market hours, showing significant volatility with no specific news identified to explain the price movement.

2026-08-03 20:06; UTC

Savara Inc is declining today, diverging from recent higher closes. Broader market indices, including the S&P 500 and Nasdaq 100, are gaining.

2026-07-31 20:06; UTC

Event

Savara Inc shares are lower despite the European Patent Office granting a patent for MOLBREEVI, effective through March 2041. The stock remains near its one-month low.

2026-07-30 20:09; UTC

Event

Savara Inc shares rise after the European Patent Office grants a patent for MOLBREEVI, providing protection until March 2041.

2026-07-29 19:47; UTC

Savara Inc's shares are lower, marking five consecutive sessions of decline. Broader market performance is mixed as traders await the Federal Reserve's interest rate decision.

2026-07-28 19:16; UTC

Savara Inc. shares are lower today amid ongoing price weakness. Broader markets like the FTSE 100 and DAX are showing resilience despite this decline.

2026-07-27 14:02; UTC

Savara Inc shares are higher during Monday's session, reaching their peak at 9:30 AM ET. No specific news was identified to explain the movement.

2026-07-24 20:02; UTC

Savara Inc shares are lower today, continuing a decline since Thursday amid high market volume. Broader market sentiment is affected by recent oil price volatility.

2026-07-21 17:41; UTC

Savara Inc. shares are advancing today amid strong trading volume. The broader market is also positive, led by gains in technology stocks.

2026-07-20 20:06; UTC

Savara Inc shares are higher, continuing their advance from Friday's close. Broader market sentiment remains mixed amid ongoing geopolitical concerns.

Akcijų palyginimas

Kainos pokytis

Savara Inc Prognozė

Kainos tikslas

By TipRanks

95.96% į viršų

12 mėnesių prognozė

Vidutinis 11.17 USD  95.96%

Aukščiausias 16 USD

Žemiausias 9 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Savara Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

292 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat